33 results about "Hepatic ischemia" patented technology

Disclosed is a method of treating liver ischemia reperfusion (I / R) injury in a subject. In some aspects, the method comprises providing a subject suffering from liver I / R injury or at risk of suffering liver I / R injury; and administering to the subject one or more heparan sulfate (HS) compounds. In some aspects, the one or more HS compounds comprises about 5 to about 18 saccharide units, optionally about 12 to about 18 saccharide units. In some aspects, the one or more HS compounds comprises about 12 saccharide units.

The invention belongs to the technical field of biological medicine and molecular biology, and particularly relates to application of a transcription factor ZHX2 in diagnosis and treatment of hepatic ischemia-reperfusion injury. Specifically, research finds that the expression of ZHX2 after ischemia reperfusion injury is reduced, and HIRI cell necrosis and generation and development of HIRI are obviously promoted by specifically knocking out Zhx2 from liver cells, which are further proved in marginal liver IRI, while the ZHX2 has a protective effect on marginal fatty liver ischemia reperfusion injury. In conclusion, the ZHX2 can be used as a biological marker and a related treatment target of the hepatic ischemia reperfusion injury, especially marginal hepatic ischemia reperfusion injury, so that the ZHX2 has good clinical application value and social benefit.

The invention relates to the technical field of medicines, in particular to application of mulberry bark extract in preparation of medicines for preventing and / or treating ischemia-reperfusion injury, and finds that morusin administration treatment can effectively relieve pathological injury of mouse liver tissue, reduce activity of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) in serum after hepatic ischemia-reperfusion, and can be used for preparing medicines for preventing and / or treating ischemia-reperfusion injury. The expression of inflammatory cytokines is inhibited, and the proportion of apoptotic cells is remarkably reduced. The invention further finds that the morusin inhibits the expression of 15-hydroxyeicosapentaenoic acid (15-HETE), and the protection effect of the morusin on the HIRI can be reversed by adding the 15-HETE, so that the morusin can be used for inhibiting the expression of the 15-hydroxyeicosapentaenoic acid (15-HETE).

The invention discloses an application of gentiopicroside in preparation of a medicine for protecting liver ischemia-reperfusion injury, discusses the protection effect of gentiopicroside on mouse liver ischemia-reperfusion injury, and preliminarily reveals a ferroptosis related molecular mechanism. The invention discloses that gentiopicroside can play a role in protecting HIRI by inhibiting ferroptosis, oxidative stress and inflammatory response, further indicates that gentiopicroside can be further used for preparing a medicine for protecting liver ischemia-reperfusion injury, and meanwhile, the invention discloses the effect of ferroptosis in HIRI, discovers a new therapeutic target, and has a good application prospect. A new thought and a new direction are provided for treatment of liver diseases.

The present invention relates to the use of a lysine methyltransferase DOT1L inhibitor in the preparation of a medicament for treating liver ischemia-reperfusion injury, belonging to the technical field of biomedicine. The lysine methyltransferase DOT1L inhibitor is SGC0946. The present invention discloses for the first time the new use of a lysine methyltransferase DOT1L inhibitor, especially SGC0946, in the preparation of a medicament for treating liver ischemia-reperfusion injury. The present invention confirms that the expression level of DOT1L in mice with liver ischemia-reperfusion injury is significantly increased, which in turn leads to a significant up-regulation of the H3K79 methylation level, a significant increase in the levels of alanine aminotransferase and aspartate aminotransferase, and the ferroptosis marker genes Ptgs2 and Chac1 are significantly up-regulated, indicating that DOT1L can be used as a target for treating liver ischemia-reperfusion injury, and a lysine methyltransferase DOT1L inhibitor can be used to prepare a medicament for treating liver ischemia-reperfusion injury.

The invention belongs to the technical field of pharmaceutical compounds, and particularly relates to an azaphenanthrone derivative with anti-hepatic ischemia-reperfusion injury activity as well as a preparation method and application of the azaphenanthrone derivative. The structural formula of the azaphenanthrone derivative is shown as a formula A, in the formula A, R1 is CHO or COOH, and R2 is H or Cl. According to the application, the azaphenanthrone derivative is extracted from an acupoint shell fungus fermentation solution, and experiments prove that the compound has the activity of resisting the hepatic ischemia-reperfusion injury, so that the compound has the potential to be developed into an active medicine for resisting the hepatic ischemia-reperfusion injury. And a new choice is provided for developing an active medicine for resisting the hepatic ischemia-reperfusion injury.

The invention discloses application of a CGAS-STING signal channel inhibitor in preparation of a medicine for preventing and treating hepatic ischemia-reperfusion injury, and relates to the technical field of biological medicine. According to the application, a cGAS-STING signal channel in macrophages is inhibited by using a cGAS inhibitor or an STING inhibitor, activation of double-stranded deoxyribonucleic acid released by a neutrophile granulocyte extracellular trapping net on a DNA induction channel is blocked, and the M1 type polarization level of the macrophages is reduced. The traditional Chinese medicine composition can effectively relieve liver inflammatory response and cell apoptosis, and a new path is provided for preventing and treating acute liver injury after liver transplantation or liver resection.

This invention belongs to the field of pharmaceutical compound technology, specifically relating to an azafibrone derivative with anti-hepatic ischemia-reperfusion injury activity, its preparation method, and its application. The structural formula of the azafibrone derivative is shown in Formula A: Among them, R 1 For CHO or COOH, R 2 The derivative is H or Cl. This application describes the extraction of an azafibrone derivative from the fermentation broth of *Cryptocaryas* fungi. Experiments have confirmed that this compound possesses anti-hepatic ischemia-reperfusion injury activity, indicating its potential to be developed into an anti-hepatic ischemia-reperfusion injury drug, providing a new option for the development of such drugs.

The invention discloses an application of S100A9 in treatment of lung injury caused by liver ischemia reperfusion. A liver ischemia reperfusion animal model is utilized to find that S100A9 is closely related to lung injury caused by liver ischemia reperfusion. Lung injury caused by liver ischemia reperfusion can be effectively relieved by knocking out the S100A9 gene or inhibiting a downstream signal channel mediated by the S100A9. In addition, it is also found that the S100A9 expression level has very strong correlation with lung injury after liver transplantation by collecting patients clinically subjected to liver transplantation. Research results of the invention show that S100A9 is a diagnosis and treatment marker for lung injury caused by hepatic ischemia reperfusion.

This invention relates to the field of biomedical materials technology and provides an application of obeticholic acid-exosome nanoparticles in the treatment of hepatic ischemia-reperfusion injury. The obeticholic acid-exosome nanoparticles are prepared by combining exosomes and obeticholic acid using an ultrasonic method, wherein the exosomes are derived from human bone marrow mesenchymal stem cells. The method for preparing the obeticholic acid-exosome nanoparticles is simple and easy to mass-produce. By utilizing exosomes derived from mesenchymal stem cells, the obeticholic acid-exosome nanoparticles improve the drug's targeting in vivo and prolong its circulation time, achieving targeted delivery of obeticholic acid to the liver, thus providing a new targeted therapeutic strategy for hepatic ischemia-reperfusion injury.

The present invention discloses an application of a PAI-1 inhibitor in the preparation of a drug for treating liver ischemia-reperfusion injury, and relates to the field of biomedicine technology. The present invention selects PAI-1 gene knockout mice and C57BL / 6 wild-type mice as experimental subjects, constructs mouse liver ischemia-reperfusion injury models respectively, and studies the function of PAI-1 in liver ischemia-reperfusion injury. The study found that after PAI-1 knockout, it can reduce liver ischemia-reperfusion injury by affecting the formation and recruitment of liver neutrophil induction network, inhibiting the inflammatory response of the liver. PAI-1 is a key gene that affects neutrophil activation and is an important target for regulating inflammatory response during the reperfusion period. Animal experiments have verified that the PAI-1 specific inhibitor PAI-039 can reduce the degree of injury of mouse liver ischemia-reperfusion, providing new ideas for the development of new drugs for preventing, alleviating and / or treating tissue ischemia-reperfusion injury.

The invention discloses application of curcumenone in preparation of a medicine for preventing and treating ischemia-reperfusion injury. The invention proposes and verifies that the caramel curcumenone can be used for preventing and treating the hepatic ischemia reperfusion injury for the first time, and the compound can effectively protect hepatic tissues and avoid liver function damage by inhibiting the oxidative stress level of the hepatic tissues after ischemia reperfusion, avoiding cell ferroptosis and improving bone marrow-derived macrophages, so that the caramel curcumenone can be used for preventing and treating the hepatic ischemia reperfusion injury. The invention provides a novel medicine with great application potential for preventing and treating ischemia reperfusion injury.

The present invention proposes the use of a bile acid derivative in the preparation of a drug for preventing and treating liver ischemia-reperfusion injury. The bile acid derivative is glycine-β-muricholic acid, which mediates the inflammation-inhibiting effect in liver ischemia-reperfusion injury through glycine-β-muricholic acid, and confirms its molecular mechanism of inhibiting macrophage pyroptosis, providing a new therapeutic target and strategy for the clinical prevention and alleviation of liver ischemia-reperfusion injury.

The invention discloses application of a disulfide death inhibitor in a medicine and the medicine, and relates to the technical field of medicines, in particular to application of the disulfide death inhibitor in preparation of a medicine for treating hepatic ischemia-reperfusion injury, and the disulfide death inhibitor is 2-deoxy-D-glucose or tris (2-carboxyethyl) phosphine. It is found for the first time that the disulfide death inhibitor (2-deoxy-D-glucose and tris (2-carboxyethyl) phosphine) has a remarkable treatment effect on the hepatic ischemia reperfusion injury, and the 2-deoxy-D-glucose and the tris (2-carboxyethyl) phosphine can effectively relieve sulfide stress in hepatic cells and cytoskeleton shrinkage caused by hepatic ischemia; further, the disulfide death of liver cells is reduced, and the liver injury recovery is favorably promoted; therefore, the disulfur death inhibitor is applied to preparation of the medicine for treating the hepatic ischemia reperfusion injury, and a new method is provided for clinical prevention and treatment of the hepatic ischemia reperfusion injury.

The invention belongs to the technical field of pharmaceutical compounds, and particularly relates to a steroid compound derived from blue-like bacteria fungi as well as a preparation method and application of the steroid compound. The structural formula of the steroid compound is shown as a formula A. The brand-new steroid compound is extracted from fermentation liquor of blue-like fungi, and experiments prove that the compound has the activity of resisting the hepatic ischemia-reperfusion injury, so that the compound has the potential to be developed into an active medicine for resisting the hepatic ischemia-reperfusion injury. And a new choice is provided for developing an active medicine for resisting the hepatic ischemia-reperfusion injury.

The present invention discloses a nanoformulation for protecting against liver ischemia-reperfusion injury and its application. The nanoformulation comprises glucose-6-phosphate disodium, an esterase-responsive charge-reversal polymer (ERP), a lipid, and DSPE-PEG-Gal. The esterase-responsive charge-reversal polymer (ERP) serves as a nanocarrier to encapsulate glucose-6-phosphate disodium to form ERP / G6P. The lipid encapsulates ERP / G6P to form a spherical core-shell structure of Lipids / ERP / G6P. DSPE-PEG-Gal assembles with Lipids / ERP / G6P to form a PEG-Lipids / ERP / G6P nanoformulation. The present invention utilizes nanoscale size effects and active targeting to enrich G6P in the liver, improving its stability and bioavailability. The polymer ERP used can be hydrolyzed by esterases, thus exhibiting good biosafety.

The invention discloses a multi-channel nanoprobe, a preparation method thereof and application of the multi-channel nanoprobe in detection of liver ischemia reperfusion injury biomarkers, and belongs to the technical field of in-situ detection and nanoprobe preparation. The nanoprobe is a functionalized metal organic framework nanomaterial which is loaded with gold nanoparticles and a fluorescent dye in sequence and is coated with a hyaluronic acid film; the metal organic framework is prepared by taking 2-methylimidazole and zinc nitrate as raw materials; raman active molecule cytochrome C is modified by the gold nanoparticles through an amidation reaction. The preparation process is simple, the cost is low, the operation is easy, the prepared multi-channel nanoprobe has high sensitivity and excellent biocompatibility, fluorescence and SERS dual-channel simultaneous detection of ATP and O2 <.-> biomarkers in the liver cell injury process can be achieved, and the application prospect is wide. The method can be used for clinically, accurately, efficiently and quickly diagnosing the liver ischemia reperfusion injury and monitoring the disease course in real time.

This invention relates to the field of biomedicine, specifically to the application of dimethylhydroquinone in improving ischemia-reperfusion-related injury of the heart and liver. 2,6-DMHQ can reduce serum ALT and AST, improve liver necrosis, and also reduce serum myocardial enzyme levels CK, CK / MB, and LDH, thereby reducing the area of ​​myocardial infarction.

The application discloses application of hsa_circ_0003258 in prevention and / or treatment of liver ischemia-reperfusion injury. The application is found by detection that the expression of hsa_circ_0003258 is significantly decreased in liver ischemia-reperfusion patients; overexpression of hsa_circ_0003258 can significantly inhibit macrophage inflammation and the apoptosis level of hepatocytes after hypoxia-reoxygenation treatment, and improve the function of hepatocytes; hsa_circ_0003258 has a protective effect on relieving liver ischemia-reperfusion injury, and has potential to become a drug for treating liver ischemia-reperfusion injury.

The invention belongs to the technical field of medical biology, and particularly relates to application of an ion channel in liver ischemia reperfusion injury aggravated by hypernatreemia. According to the application of the ion channel as a target for screening, preventing, relieving or / and treating the liver ischemia-reperfusion injury aggravated by the hypernatreemia, the ion channel is at least one of ENaC and NCX-1. Research finds that the hypernatremia aggravates ischemia reperfusion injury of the liver by activating an ENaC-NCX-1-NLRP3 signal channel, resulting in ROS increase, inflammation and aggravation of apoptosis, and the application of an inhibitor Amil of ENaC and an inhibitor SN-6 of NCX-1 can reduce the hypernatremia aggravated liver IRI, which brings a new therapeutic scheme for a donor of the hypernatremia, and has a broad application prospect. The improvement of the liver utilization rate of a hypernatremia donor is facilitated.

The application belongs to the field of biological medicine, and discloses application of echinocystic acid in preparation of a medicine for preventing and treating liver ischemia-reperfusion injury. The application proves that the echinocystic acid significantly improves liver tissue injury, reduces serum ALT and AST levels, and reduces cell apoptosis through a mouse liver IRI model. It is found that the echinocystic acid activates the p38 MAPK signal pathway by inhibiting PTPN1, thereby activating Nrf2 and enhancing PINK1 / Parkin-mediated mitochondrial autophagy. In addition, the echinocystic acid promotes DRP1 phosphorylation and enhances the transfer of DRP1 to mitochondria, thereby reducing oxidative stress and inflammatory response. It is shown that the echinocystic acid regulates mitochondrial autophagy through the PTPN1 / p38 MAPK / Nrf2 pathway, has a significant liver protection effect, and provides a new idea for the treatment of IRI.

The invention discloses a biomarker for hepatic ischemia reperfusion injury based on proteomics, the biomarker is NGP (Neutrophil Granule Protein), and the biomarker can be used for early diagnosis and prevention, prognosis monitoring and judgment and the like of complications after hepatic resection.

Disclosed are an amlodipine drug targeted delivery system and a preparation method therefor. The targeted delivery system can improve the targeting property of amlodipine in preventing hepatic ischemia-reperfusion injury and is simple to prepare, highly feasible, and highly practical. The amlodipine drug targeted delivery system (Am@EXOs) prepared in the present invention enables a targeted distribution of amlodipine in the livers of hepatic ischemia-reperfusion injury model mice and precise inhibition of calcium ion overload within hepatocytes by means of a minimum dose of amlodipine, thereby reducing cell injury, improving the targeting property of amlodipine in preventing hepatic ischemia-reperfusion injury, and reducing the cost of using amlodipine.

The application discloses a biomarker of liver ischemia-reperfusion injury based on proteomics, and the biomarker is neutrophil granule protein (NGP), which can be used for early diagnosis and prevention of post-hepatectomy complications, prognosis monitoring and judgment, etc.

The invention provides a traditional Chinese medicine composition for resisting hepatic ischemia-reperfusion injury and application of the traditional Chinese medicine composition, and belongs to the technical field of traditional Chinese medicine compositions. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 1 part of liquorice root, 1 part of radix salviae miltiorrhizae and 1 part of radix paeoniae alba. Salvia miltiorrhiza has the effects of promoting blood circulation to remove blood stasis, cooling blood to relieve pain and resisting oxidation; radix paeoniae alba can nourish blood and liver (supplement blood and nourish liver) and inhibit inflammatory response; the liquorice has the functions of detoxifying and regulating the medicine property; salvia miltiorrhiza, radix paeoniae alba and liquorice cooperate to achieve the effects of cooling blood and dispersing blood stasis, clearing away heat and toxic materials, replenishing blood and nourishing liver, and can effectively resist hepatic ischemia reperfusion injury.

This invention discloses a method for modifying lipid vesicles with an amphiphilic polymer containing N-oxide teramine groups. The amphiphilic polymer is OPDEA-PCL. OPDEA-PCL is used to modify synthetic liposomes, yielding amphiphilic polymer-synthetic liposome nanoparticles. OPDEA-PCL is also used to modify natural exosomes, yielding amphiphilic polymer-exosome nanoparticles. The amphiphilic polymer-synthetic liposomes of this invention possess active liver and lung targeting functions. This invention, through the engineered modification of exosomes with OPDEA-PCL, accurately guides exosomes to the liver regions requiring treatment, thereby enhancing the repair effect of exosomes on liver ischemia-reperfusion injury.

The present application relates to a nucleic acid molecule comprising a first nucleic acid sequence comprising at least a portion of a 5′ untranslated region (5′ UTR) of a carboxylesterase gene and a second nucleic acid sequence encoding a protein of interest, where the second nucleic acid sequence is heterologous to and operatively coupled to the first nucleic acid sequence. Also disclosed are methods of expressing a protein of interest in a target cell, methods of treating subject for cardiac ischemia or hepatic ischemia, and methods of identifying a nucleic acid sequence capable of selectively enhancing translation of a heterologous protein of interest in a target cell.

The invention belongs to the technical field of biological medicines, and particularly relates to application of an inhibitor targeting an Hnf4 alpha os gene in liver macrophages in preparation of a medicine for preventing and treating liver ischemia-reperfusion injury. According to the application disclosed by the invention, the Hnf4 alpha os gene in the targeted liver macrophage is specifically knocked down or knocked out, so that the expression of the Hnf4 alpha os gene is inhibited, and the injury of a liver ischemia-reperfusion injury model can be remarkably improved; the reagent (an inhibitor of the Hnf4 alpha os gene in the targeted liver macrophage) for specifically knocking down or knocking out the Hnf4 alpha os gene in the targeted liver macrophage can be applied to preparation of the medicine for preventing and treating the hepatic ischemia reperfusion injury.

Methods for treating hepatic ischemia-reperfusion (I / R) injury in a subject are disclosed. In some embodiments, the methods include providing a subject suffering from or at risk of suffering from hepatic I / R injury; and administering to the subject one or more heparan sulfate (HS) compounds. In some embodiments, the one or more HS compounds comprise about 5 to about 18 sugar units, optionally about 12 to about 18 sugar units. In some embodiments, the one or more HS compounds comprise about 12 sugar units.

The use of 2,6-DMHQ in ischemia-reperfusion-related injuries, preferably against cardiac and hepatic ischemia-reperfusion injuries. 2,6-DMHQ can reduce serum ALT and AST and ameliorate liver necrosis. 2,6-DMHQ can also reduce the cardiac enzyme profile, including CK, CK / MB and LDH, and reduce myocardial infarct size.